계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Vasopharm
About
Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.
- 1 - 10
Details
- Last Funding Type
- Private Equity（PE）
- Last Funding Money Raised
- €9.50M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jul 1, 1998
- Number Of Employee
- 1 - 10
- Operating Status
- Active
vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 11, 2019 | Private Equity（PE） | €9.50M | 3 |
|
— | Detail |
| Jan 21, 2016 | Series G | €20M | 1 | — | — | Detail |
| Jun 24, 2013 | Series F | $6.50M | 1 | — | — | Detail |
| Jan 30, 2006 | Series B | $11.80M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Private Equity（PE） |
Future Capital Development Fund
|
— | Private Equity（PE） |
Bayern Kapital
|
— | Private Equity（PE） |
